Nanobiotix presents mouse data on Nanoprimer boosting LNP-DNA bioavailability, reducing liver toxicity

• Nanobiotix disclosed new preclinical mouse data on its Nanoprimer platform, with results presented at 2026 AACR Annual Meeting.
• Nanoprimer pre-treatment supported improved systemic exposure for LNP-delivered DNA immunotherapy versus LNP-DNA alone.
• Study also indicated reduced liver-related toxicity signals, addressing a key limitation that can constrain dosing and development of LNP-based therapies.
• Data showed a dampened inflammatory response linked to innate immune activation, which could improve tolerability for repeat administration.
• Nanobiotix positioned findings as added proof of concept to support partner collaborations and internal pipeline work in extrahepatic delivery.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nanobiotix SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604200230PRIMZONEFULLFEED9692538) on April 20, 2026, and is solely responsible for the information contained therein.